Northern, WI  12/14/2012 (BasicsMedia)  —  Thursday movers were about IPO’s and Biotech which is normal for December and any distraction from Fiscal Cliff talk is refreshing…..Thank You Mr. Musk.

 SolarCity (NASDAQ:SCTY) – Shares are nearly 47% higher at $11.79 after the $8 IPO price.  (Click Here for LIVE Quote)  Elon Musk  an American entrepreneur and inventor best known for founding SpaceX, and co-founding Tesla Motors and PayPal (initially known as X.com).  Chairman of SolarCity (NASDAQ:SCTY) which came public today via IPO and rang the opening bell this morning.

The IPO would value the California-based company at about $1 billion, or about 8 times sales in the 12 months through September. That compares with an average price-to-sales multiple of about 0.4 for publicly traded companies such as Real Goods Solar (NASDAQ:RSOL)  and First Solar (NASDAQ:FSLR).   SolarCity is pushing ahead with its offering after completing the most equipment installations in California, the U.S.’s biggest solar-power market.

Oncolytics Biotech (NASDAQ:ONCY) jumped 22% on Thursday after the company announced positive top line data for the first endpoint in a randomized Phase III study of its Reolysin drug for head and neck cancers. The study focused on Reolysin in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers, the company said. “We are delighted to have obtained statistically significant data for Reolysin in a randomized clinical setting,” the company said.

Supermedia (NASDAQ:SPMD) Shares were higher Thursday trading from the mid $2 p/s level closing at $3.39, a good Seeking Alpha article by Glen Bradford (Click Here to Read) helped push shares higher and identify value as the old the former Yellow Pages Co… emerge from the dreck of bankruptcy.  This stock has come a long way.  Worth watching as this former Yellow Pages operator try to get revenue traction via local web sales to small businesses they used to cater to..

Disclaimer:  We have no position in any stock mentioned here.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.